Bupivacaine HCl PK and Safety in Augmentation Mammoplasty

• ClinicalTrials.gov Identifier: NCT03705065
• Recruitment Status: Completed
• First Posted: October 15, 2018
• Last Update Posted: December 7, 2018
• Sponsor: Heron Therapeutics
• Information provided by (Responsible Party): Heron Therapeutics

Study Description

Brief Summary:

This is a Phase 4, randomized, open-label study of bupivacaine HCl administered either by instillation into the surgical site or by injection into the surgical site in subjects undergoing bilateral submuscular augmentation mammoplasty under general anesthesia.

Condition or disease	Intervention/treatment	Phase
Analgesia	Drug: Bupivacaine HCl	Phase 4

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 30 participants
• Allocation: Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 4, Randomized, Open-Label Study of the Pharmacokinetics and Tolerability of Bupivacaine HCl Following One of Two Routes of Administration in Subjects Undergoing Augmentation Mammoplasty
• Actual Study Start Date: September 19, 2018
• Actual Primary Completion Date: October 8, 2018
• Actual Study Completion Date: November 5, 2018

Arms and Interventions

Arm	Intervention/treatment
Experimental: Treatment Group 1; Bupivacaine HCI by instillation into each pectoral pocket.	Drug: Bupivacaine HCl; Bupivacaine HCl without epinephrine 0.25%, 60 mL (30 mL per pectoral pocket)
Experimental: Treatment Group 2; Bupivacaine HCI by injection into each pectoral pocket.	Drug: Bupivacaine HCl; Bupivacaine HCl without epinephrine 0.25%, 60 mL (30 mL per pectoral pocket)

Outcome Measures

Primary Outcome Measures :

1. Maximum Observed Plasma Concentration (Cmax) [ Time Frame: Baseline through 72 hours after start of study drug administration ]
2. Area Under the Concentration-time Curve From Time 0 to the Last Collection Time After Study Drug Administration (AUC Last) [ Time Frame: Baseline through 72 hours after start of study drug administration ]
3. Area Under the Concentration-time Curve From Time 0 to Infinity After Study Drug Administration (AUC∞) [ Time Frame: Baseline through 72 hours after start of study drug administration ]
4. Time to Maximum Plasma Concentration (Tmax) [ Time Frame: Baseline through 72 hours after start of study drug administration ]
5. The Apparent Terminal Elimination Rate Constant (λz) [ Time Frame: Baseline through 72 hours after start of study drug administration ]
6. The Apparent Terminal Elimination Half-life (t1/2el) [ Time Frame: Baseline through 72 hours after start of study drug administration ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Is scheduled to undergo primary bilateral submuscular augmentation mammoplasty with saline or silicone smooth implants with a volume of 300 to 500 mL, inclusive.
• Has an American Society of Anesthesiologists Physical Status of I, II, or III.
• Female subjects are eligible only if not pregnant, not lactating, not planning to become pregnant during the study, sterile; or using acceptable contraceptives.

Exclusion Criteria:

• Has a planned concurrent surgical procedure (eg, mastopexy).
• Has a planned concurrent reconstructive procedure status post breast cancer therapy.
• Has a pre-existing concurrent acute or chronic painful physical/restrictive condition expected to require analgesic treatment in the postoperative period for pain that is not strictly related to the augmentation mammoplasty.
• Has a contraindication or a known or suspected history of hypersensitivity or clinically significant idiosyncratic reaction to required study medications.
• Has been administered bupivacaine within 5 days prior to the scheduled surgery.
• Has been administered any local anesthetic within 72 hours prior to the scheduled surgery.
• Has a medical condition such that, in the opinion of the Investigator, participating in the study would pose a health risk to the subject or confound the postoperative assessments.
• As per subject history and/or medical records, has active infection or is currently undergoing treatment for Hepatitis B, Hepatitis C, or human immunodeficiency virus (HIV).
• Has uncontrolled anxiety, psychiatric, or neurological disorder.
• Had a malignancy in the last year, with the exception of nonmetastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.
• Has a known or suspected history of drug abuse, a positive drug screen on the day of surgery, or a recent history of alcohol abuse. Note: Subjects with a positive drug screen who are taking an allowed, prescribed medication that is known to result in a positive drug test (eg, amphetamine and dextroamphetamine for attention-deficit/hyperactivity disorder, benzodiazepine for anxiety disorder) may be eligible for participation in the study at the discretion of the Sponsor. Subjects taking any marijuana (medical or recreational) are not allowed to participate in the study.
• Received an investigational product or device in a clinical trial within 30 days or within 5 elimination half-lives.
• Has undergone 3 or more surgeries within 12 months.
• Has a body mass index (BMI) >35 kg/m2.

Contacts and Locations

Locations

United States, Texas

Hermann Drive Surgical Hospital

Houston, Texas, United States, 77027

Sponsors and Collaborators

Heron Therapeutics

More Information

• Responsible Party: Heron Therapeutics
• ClinicalTrials.gov Identifier: NCT03705065
• Other Study ID Numbers: BUPI-502
• First Posted: October 15, 2018
• Last Update Posted: December 7, 2018
• Last Verified: December 2018

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Undecided

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Heron Therapeutics:

augmentation mammoplasty

Additional relevant MeSH terms:

Bupivacaine; Anesthetics, Local; Anesthetics; Central Nervous System Depressants; Physiological Effects of Drugs; Sensory System Agents; Peripheral Nervous System Agents